The diagnosis and treatment of osteoporosis: future prospects.

[1]  F. Casanueva,et al.  Growth Hormone Secretagogues: Physiological Role and Clinical Utility , 1999, Trends in Endocrinology & Metabolism.

[2]  K. Lau,et al.  Molecular Mechanism of Action of Fluoride on Bone Cells , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  S. Cummings,et al.  Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. , 1998, The New England journal of medicine.

[4]  J. Bilezikian,et al.  Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. , 1998, The Journal of clinical endocrinology and metabolism.

[5]  L. Kuller,et al.  Genetic Variation in α2HS-Glycoprotein Is Related to Calcaneal Broadband Ultrasound Attenuation in Older Women , 1998, Calcified Tissue International.

[6]  S. Mohan,et al.  Treatment with the Oral Growth Hormone Secretagogue MK‐677 Increases Markers of Bone Formation and Bone Resorption in Obese Young Males , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  David Housman,et al.  Why pharmacogenomics? Why now? , 1998, Nature Biotechnology.

[8]  R. Lindsay,et al.  Is Parathyroid Hormone a Therapeutic Option for Osteoporosis? A Review of the Clinical Evidence , 1998, Calcified Tissue International.

[9]  T. Spector,et al.  Genes control the cessation of a woman's reproductive life: a twin study of hysterectomy and age at menopause. , 1998, The Journal of clinical endocrinology and metabolism.

[10]  J. Gerhart,et al.  Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[11]  G. Poste.  Molecular medicine and information–based targeted healthcare , 1998, Nature Biotechnology.

[12]  William A. Haseltine,et al.  The power of genomics to transform the biotechnology industry , 1998, Nature Biotechnology.

[13]  S. Crooke.  Optimizing the impact of genomics on drug discovery and development , 1998, Nature Biotechnology.

[14]  B. L. Riggs,et al.  A Unitary Model for Involutional Osteoporosis: Estrogen Deficiency Causes Both Type I and Type II Osteoporosis in Postmenopausal Women and Contributes to Bone Loss in Aging Men , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  J. Drews.  Biotechnology's metamorphosis into a drug discovery industry , 1998, Nature Biotechnology.

[16]  S. Grant,et al.  Collagen Iα1 Sp1 Polymorphism, Bone Mass, and Bone Turnover in Healthy French Premenopausal Women: The OFELY Study , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  R. Langer,et al.  Drug delivery and targeting. , 1998, Nature.

[18]  R. Dodds,et al.  Cathepsin K mRNA Detection Is Restricted to Osteoclasts During Fetal Mouse Development , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  T. Guise,et al.  Cancer and bone. , 1998, Endocrine reviews.

[20]  C. Christiansen,et al.  Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. , 1997, The New England journal of medicine.

[21]  V. Goldberg,et al.  Genetic determination of bone density , 1997, The Lancet.

[22]  S. Bruder,et al.  Monoclonal antibodies reactive with human osteogenic cell surface antigens. , 1997, Bone.

[23]  T Friedmann,et al.  Overcoming the obstacles to gene therapy. , 1997, Scientific American.

[24]  G. Karsenty,et al.  Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differentiation , 1997, Cell.

[25]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[26]  D. Prockop.  Marrow Stromal Cells as Stem Cells for Nonhematopoietic Tissues , 1997, Science.

[27]  M. Kumegawa,et al.  Cathepsin K Antisense Oligodeoxynucleotide Inhibits Osteoclastic Bone Resorption* , 1997, The Journal of Biological Chemistry.

[28]  N Risch,et al.  The Future of Genetic Studies of Complex Human Diseases , 1996, Science.

[29]  B. Gelb,et al.  Pycnodysostosis, a Lysosomal Disease Caused by Cathepsin K Deficiency , 1996, Science.

[30]  D. Moskowitz.  Genetic screening and diagnosis of disease. , 1996, Molecular medicine today.

[31]  S. Goldstein,et al.  Stimulation of new bone formation by direct transfer of osteogenic plasmid genes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[32]  L. Donahue,et al.  Genetic variability in adult bone density among inbred strains of mice. , 1996, Bone.

[33]  J Dequeker,et al.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. , 1995, The New England journal of medicine.

[34]  G. McCabe,et al.  Peak bone mass in young women , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[35]  M. Khoury,et al.  Epidemiological evaluation of the use of genetics to improve the predictive value of disease risk factors. , 1995, American journal of human genetics.

[36]  C. Cooper,et al.  Perspective how many women have osteoporosis? , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[37]  Claus Christiansen,et al.  Diagnosis of Osteoporosis , 1992, Southern medical journal.

[38]  C. Slemenda,et al.  Genetic determinants of bone mass in adult women: A reevaluation of the twin model and the potential importance of gene interaction on heritability estimates , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[39]  S. Mohan,et al.  Bone growth factors. , 1991, Clinical orthopaedics and related research.

[40]  C. Libanati,et al.  Fluoride therapy for osteoporosis promotes a progressive increase in spinal bone density , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[41]  P. Brinckmann,et al.  Prediction of the Compressive Strength of Human Lumbar Vertebrae , 1989, Spine.

[42]  M. D. de Rie,et al.  The pathogenesis of psoriasis: immunological facts and speculations. , 1999, Immunology today.

[43]  J. Whitfield,et al.  Anabolic treatments for osteoporosis , 1998 .

[44]  A. Stewart.  Baboons provide clues to osteoporosis. , 1998, Molecular medicine today.

[45]  S. Ralston.  Do genetic markers aid in risk assessment? , 1998, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.

[46]  T. Spector,et al.  Genetic influence on bone turnover in postmenopausal twins. , 1996, The Journal of clinical endocrinology and metabolism.

[47]  John P. Bilezikian,et al.  Principles of Bone Biology , 1996 .

[48]  J. Kanis,et al.  Perspective : The diagnosis of osteoporosis , 1994 .

[49]  C. Turner,et al.  ON FLUORIDE AND BONE STRENGTH. RESPONSE , 1993 .